Accera Inc.'s metabolic-focused Alzheimer's candidate, AC-1204, has foundered in the company's phase III NOURISH AD trial, failing to deliver statistically significant improvements in memory and cognition vs. placebo for people with mild to moderate Alzheimer's disease. A reformulation of the drug between a successful phase II trial and the phase III study yielded suboptimal exposure, contributing to the lack of efficacy, the company said.